Jin Qian obtained her Ph.D. from Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2007. Following that Dr. Qian joined AstraZeneca and has worked as a researcher in its Innovation Center China (ICC).
Her works focus on translational research and studies of mTOR and PAPR pathways using in vitro models. In 2009, she received the chance to do a one-year postdoctoral training fellowship at the University Colorado School of Medicine and Cancer Center in Denver, working in Dr. Fred Hirsch’s Biomarker nalysis lab. Her project in Dr. Hirsch’s lab focuses on evaluating the activation of the IGF-IR pathway in NSCLC to predict primary resistance to EGFR TKI.